AstraZeneca's COVID prevention drug application gets EU fast-track assessment
FILE PHOTO: A vial labelled "AstraZeneca COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
(Reuters) - AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
The submission was based on positive data from a late-stage trial that showed the drug helped reduce the incidence of COVID-19 in immunocompromised patients.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sonia Cheema)